<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Wed, 10 Jun 2026 10:30:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Ryder Named to America’s Greatest Workplaces List by Newsweek</title>
   <link>http://www.streetinsider.com/Press+Releases/Ryder+Named+to+America%E2%80%99s+Greatest+Workplaces+List+by+Newsweek/26628266.html</link>
   <description>
&lt;ul class=&quot;bwlistdisc&quot;&gt;
&lt;li&gt;
Ryder recognized for cultivating a high-performing workplace where employees succeed through capability, engagement, and opportunity

&lt;/li&gt;
&lt;li&gt;
Ryder honored as one of America’s Greatest Workplaces for third year in a row

&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
Ryder System, Inc. (NYSE: R) earns a spot on America’s Greatest Workplaces list by Newsweek&lt;i&gt; &lt;/i&gt;for 2026, celebrating the company’s third consecutive year receiving this honor. The annual recognition highlights Ryder’s ongoing commitment to fostering a supportive and innovative workplace where our people can excel and thrive.

&lt;/p&gt;&lt;p id=&quot;news-body-cta&quot;&gt;This press release features multimedia. View the full release here: &lt;a target=&quot;_blank&quot; href=&quot;https://www.businesswire.com/news/home/20260610358756/en/&quot; rel=&quot;nofollow&quot;&gt;https://www.businesswire.com/news/home/20260610358756/en/&lt;/a&gt;&lt;/p&gt;&lt;div id=&quot;bwbodyimg&quot; style=&quot;width: 480px; float:left; padding-left:0px; padding-right:20px;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ryder+Named+to+America%E2%80%99s+Greatest+Workplaces+List+by+Newsweek/26628266.html</guid>
   <pubDate>Wed, 10 Jun 2026 10:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder Named to America’s Greatest Workplaces List by Newsweek</title>
   <link>http://www.streetinsider.com/Press+Releases/Ryder+Named+to+America%E2%80%99s+Greatest+Workplaces+List+by+Newsweek/26628266.html</link>
   <description>
&lt;ul class=&quot;bwlistdisc&quot;&gt;
&lt;li&gt;
Ryder recognized for cultivating a high-performing workplace where employees succeed through capability, engagement, and opportunity

&lt;/li&gt;
&lt;li&gt;
Ryder honored as one of America’s Greatest Workplaces for third year in a row

&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
Ryder System, Inc. (NYSE: R) earns a spot on America’s Greatest Workplaces list by Newsweek&lt;i&gt; &lt;/i&gt;for 2026, celebrating the company’s third consecutive year receiving this honor. The annual recognition highlights Ryder’s ongoing commitment to fostering a supportive and innovative workplace where our people can excel and thrive.

&lt;/p&gt;&lt;p id=&quot;news-body-cta&quot;&gt;This press release features multimedia. View the full release here: &lt;a target=&quot;_blank&quot; href=&quot;https://www.businesswire.com/news/home/20260610358756/en/&quot; rel=&quot;nofollow&quot;&gt;https://www.businesswire.com/news/home/20260610358756/en/&lt;/a&gt;&lt;/p&gt;&lt;div id=&quot;bwbodyimg&quot; style=&quot;width: 480px; float:left; padding-left:0px; padding-right:20px;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ryder+Named+to+America%E2%80%99s+Greatest+Workplaces+List+by+Newsweek/26628266.html</guid>
   <pubDate>Wed, 10 Jun 2026 10:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder Named to America’s Greatest Workplaces List by Newsweek</title>
   <link>http://www.streetinsider.com/Business+Wire/Ryder+Named+to+America%E2%80%99s+Greatest+Workplaces+List+by+Newsweek/26628266.html</link>
   <description>
&lt;ul class=&quot;bwlistdisc&quot;&gt;
&lt;li&gt;
Ryder recognized for cultivating a high-performing workplace where employees succeed through capability, engagement, and opportunity

&lt;/li&gt;
&lt;li&gt;
Ryder honored as one of America’s Greatest Workplaces for third year in a row

&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
Ryder System, Inc. (NYSE: R) earns a spot on America’s Greatest Workplaces list by Newsweek&lt;i&gt; &lt;/i&gt;for 2026, celebrating the company’s third consecutive year receiving this honor. The annual recognition highlights Ryder’s ongoing commitment to fostering a supportive and innovative workplace where our people can excel and thrive.

&lt;/p&gt;&lt;p id=&quot;news-body-cta&quot;&gt;This press release features multimedia. View the full release here: &lt;a target=&quot;_blank&quot; href=&quot;https://www.businesswire.com/news/home/20260610358756/en/&quot; rel=&quot;nofollow&quot;&gt;https://www.businesswire.com/news/home/20260610358756/en/&lt;/a&gt;&lt;/p&gt;&lt;div id=&quot;bwbodyimg&quot; style=&quot;width: 480px; float:left; padding-left:0px; padding-right:20px;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ryder+Named+to+America%E2%80%99s+Greatest+Workplaces+List+by+Newsweek/26628266.html</guid>
   <pubDate>Wed, 10 Jun 2026 10:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder Named to America’s Greatest Workplaces List by Newsweek</title>
   <link>http://www.streetinsider.com/Business+Wire/Ryder+Named+to+America%E2%80%99s+Greatest+Workplaces+List+by+Newsweek/26628266.html</link>
   <description>
&lt;ul class=&quot;bwlistdisc&quot;&gt;
&lt;li&gt;
Ryder recognized for cultivating a high-performing workplace where employees succeed through capability, engagement, and opportunity

&lt;/li&gt;
&lt;li&gt;
Ryder honored as one of America’s Greatest Workplaces for third year in a row

&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
Ryder System, Inc. (NYSE: R) earns a spot on America’s Greatest Workplaces list by Newsweek&lt;i&gt; &lt;/i&gt;for 2026, celebrating the company’s third consecutive year receiving this honor. The annual recognition highlights Ryder’s ongoing commitment to fostering a supportive and innovative workplace where our people can excel and thrive.

&lt;/p&gt;&lt;p id=&quot;news-body-cta&quot;&gt;This press release features multimedia. View the full release here: &lt;a target=&quot;_blank&quot; href=&quot;https://www.businesswire.com/news/home/20260610358756/en/&quot; rel=&quot;nofollow&quot;&gt;https://www.businesswire.com/news/home/20260610358756/en/&lt;/a&gt;&lt;/p&gt;&lt;div id=&quot;bwbodyimg&quot; style=&quot;width: 480px; float:left; padding-left:0px; padding-right:20px;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ryder+Named+to+America%E2%80%99s+Greatest+Workplaces+List+by+Newsweek/26628266.html</guid>
   <pubDate>Wed, 10 Jun 2026 10:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder CEO John Diez to Address Wells Fargo 16th Industrials &amp;amp; Materials Conference</title>
   <link>http://www.streetinsider.com/Press+Releases/Ryder+CEO+John+Diez+to+Address+Wells+Fargo+16th+Industrials+%26amp%3B+Materials+Conference/26595130.html</link>
   <description>
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
Ryder System, Inc. (NYSE: R) CEO John Diez to address the Wells Fargo 16th Industrials &amp;amp; Materials Conference.

&lt;/p&gt;&lt;p id=&quot;news-body-cta&quot;&gt;This press release features multimedia. View the full release here: &lt;a target=&quot;_blank&quot; href=&quot;https://www.businesswire.com/news/home/20260603064216/en/&quot; rel=&quot;nofollow&quot;&gt;https://www.businesswire.com/news/home/20260603064216/en/&lt;/a&gt;&lt;/p&gt;&lt;div id=&quot;bwbodyimg&quot; style=&quot;width: 320px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;&quot;&gt;&lt;img src=&quot;https://mms.businesswire.com/media/20260603064216/en/2821924/4/John_Diez_1_lowres-web.jpg&quot; alt=&quot;Ryder System, Inc. CEO John J. Diez&quot; /&gt;&lt;p style=&quot;font-size:85%;&quot;&gt;Ryder System, Inc. CEO John J. Diez&lt;/p&gt;&lt;/div&gt;&lt;table cellspacing=&quot;0&quot; class=&quot;bwtablemarginb bwblockalignl bwwidth100&quot;&gt;
&lt;tr&gt;
&lt;td class=&quot;bwwidth10&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;b&gt;Who: &lt;/b&gt;&lt;/td&gt;
&lt;td class=&quot;bwvertalignt bwpadl0 bwwidth90&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;p class=&quot;bwcellpmargin&quot;&gt;
Ryder System, Inc. CEO John Diez

&lt;/p&gt;

&lt;/td&gt;

&lt;/tr&gt;
&lt;tr&gt;
&lt;td class=&quot;bwwidth10&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;b&gt;What:&lt;/b&gt;&lt;/td&gt;
&lt;td class=&quot;bwvertalignt bwpadl0 bwwidth90&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;p class=&quot;bwcellpmargin&quot;&gt;
Wells Fargo 16th Industrials &amp;amp; Materials Conference

&lt;/p&gt;

&lt;/td&gt;

&lt;/tr&gt;
&lt;tr&gt;
&lt;td class=&quot;bwwidth10&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;b&gt;When:&lt;/b&gt; &lt;/td&gt;
&lt;td class=&quot;bwvertalignt bwpadl0 bwwidth90&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ryder+CEO+John+Diez+to+Address+Wells+Fargo+16th+Industrials+%26amp%3B+Materials+Conference/26595130.html</guid>
   <pubDate>Wed, 03 Jun 2026 06:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder CEO John Diez to Address Wells Fargo 16th Industrials &amp;amp; Materials Conference</title>
   <link>http://www.streetinsider.com/Press+Releases/Ryder+CEO+John+Diez+to+Address+Wells+Fargo+16th+Industrials+%26amp%3B+Materials+Conference/26595130.html</link>
   <description>
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
Ryder System, Inc. (NYSE: R) CEO John Diez to address the Wells Fargo 16th Industrials &amp;amp; Materials Conference.

&lt;/p&gt;&lt;p id=&quot;news-body-cta&quot;&gt;This press release features multimedia. View the full release here: &lt;a target=&quot;_blank&quot; href=&quot;https://www.businesswire.com/news/home/20260603064216/en/&quot; rel=&quot;nofollow&quot;&gt;https://www.businesswire.com/news/home/20260603064216/en/&lt;/a&gt;&lt;/p&gt;&lt;div id=&quot;bwbodyimg&quot; style=&quot;width: 320px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;&quot;&gt;&lt;img src=&quot;https://mms.businesswire.com/media/20260603064216/en/2821924/4/John_Diez_1_lowres-web.jpg&quot; alt=&quot;Ryder System, Inc. CEO John J. Diez&quot; /&gt;&lt;p style=&quot;font-size:85%;&quot;&gt;Ryder System, Inc. CEO John J. Diez&lt;/p&gt;&lt;/div&gt;&lt;table cellspacing=&quot;0&quot; class=&quot;bwtablemarginb bwblockalignl bwwidth100&quot;&gt;
&lt;tr&gt;
&lt;td class=&quot;bwwidth10&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;b&gt;Who: &lt;/b&gt;&lt;/td&gt;
&lt;td class=&quot;bwvertalignt bwpadl0 bwwidth90&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;p class=&quot;bwcellpmargin&quot;&gt;
Ryder System, Inc. CEO John Diez

&lt;/p&gt;

&lt;/td&gt;

&lt;/tr&gt;
&lt;tr&gt;
&lt;td class=&quot;bwwidth10&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;b&gt;What:&lt;/b&gt;&lt;/td&gt;
&lt;td class=&quot;bwvertalignt bwpadl0 bwwidth90&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;p class=&quot;bwcellpmargin&quot;&gt;
Wells Fargo 16th Industrials &amp;amp; Materials Conference

&lt;/p&gt;

&lt;/td&gt;

&lt;/tr&gt;
&lt;tr&gt;
&lt;td class=&quot;bwwidth10&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;b&gt;When:&lt;/b&gt; &lt;/td&gt;
&lt;td class=&quot;bwvertalignt bwpadl0 bwwidth90&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ryder+CEO+John+Diez+to+Address+Wells+Fargo+16th+Industrials+%26amp%3B+Materials+Conference/26595130.html</guid>
   <pubDate>Wed, 03 Jun 2026 06:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder CEO John Diez to Address Wells Fargo 16th Industrials &amp;amp; Materials Conference</title>
   <link>http://www.streetinsider.com/Business+Wire/Ryder+CEO+John+Diez+to+Address+Wells+Fargo+16th+Industrials+%26amp%3B+Materials+Conference/26595130.html</link>
   <description>
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
Ryder System, Inc. (NYSE: R) CEO John Diez to address the Wells Fargo 16th Industrials &amp;amp; Materials Conference.

&lt;/p&gt;&lt;p id=&quot;news-body-cta&quot;&gt;This press release features multimedia. View the full release here: &lt;a target=&quot;_blank&quot; href=&quot;https://www.businesswire.com/news/home/20260603064216/en/&quot; rel=&quot;nofollow&quot;&gt;https://www.businesswire.com/news/home/20260603064216/en/&lt;/a&gt;&lt;/p&gt;&lt;div id=&quot;bwbodyimg&quot; style=&quot;width: 320px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;&quot;&gt;&lt;img src=&quot;https://mms.businesswire.com/media/20260603064216/en/2821924/4/John_Diez_1_lowres-web.jpg&quot; alt=&quot;Ryder System, Inc. CEO John J. Diez&quot; /&gt;&lt;p style=&quot;font-size:85%;&quot;&gt;Ryder System, Inc. CEO John J. Diez&lt;/p&gt;&lt;/div&gt;&lt;table cellspacing=&quot;0&quot; class=&quot;bwtablemarginb bwblockalignl bwwidth100&quot;&gt;
&lt;tr&gt;
&lt;td class=&quot;bwwidth10&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;b&gt;Who: &lt;/b&gt;&lt;/td&gt;
&lt;td class=&quot;bwvertalignt bwpadl0 bwwidth90&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;p class=&quot;bwcellpmargin&quot;&gt;
Ryder System, Inc. CEO John Diez

&lt;/p&gt;

&lt;/td&gt;

&lt;/tr&gt;
&lt;tr&gt;
&lt;td class=&quot;bwwidth10&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;b&gt;What:&lt;/b&gt;&lt;/td&gt;
&lt;td class=&quot;bwvertalignt bwpadl0 bwwidth90&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;p class=&quot;bwcellpmargin&quot;&gt;
Wells Fargo 16th Industrials &amp;amp; Materials Conference

&lt;/p&gt;

&lt;/td&gt;

&lt;/tr&gt;
&lt;tr&gt;
&lt;td class=&quot;bwwidth10&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;b&gt;When:&lt;/b&gt; &lt;/td&gt;
&lt;td class=&quot;bwvertalignt bwpadl0 bwwidth90&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ryder+CEO+John+Diez+to+Address+Wells+Fargo+16th+Industrials+%26amp%3B+Materials+Conference/26595130.html</guid>
   <pubDate>Wed, 03 Jun 2026 06:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder CEO John Diez to Address Wells Fargo 16th Industrials &amp;amp; Materials Conference</title>
   <link>http://www.streetinsider.com/Business+Wire/Ryder+CEO+John+Diez+to+Address+Wells+Fargo+16th+Industrials+%26amp%3B+Materials+Conference/26595130.html</link>
   <description>
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
Ryder System, Inc. (NYSE: R) CEO John Diez to address the Wells Fargo 16th Industrials &amp;amp; Materials Conference.

&lt;/p&gt;&lt;p id=&quot;news-body-cta&quot;&gt;This press release features multimedia. View the full release here: &lt;a target=&quot;_blank&quot; href=&quot;https://www.businesswire.com/news/home/20260603064216/en/&quot; rel=&quot;nofollow&quot;&gt;https://www.businesswire.com/news/home/20260603064216/en/&lt;/a&gt;&lt;/p&gt;&lt;div id=&quot;bwbodyimg&quot; style=&quot;width: 320px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;&quot;&gt;&lt;img src=&quot;https://mms.businesswire.com/media/20260603064216/en/2821924/4/John_Diez_1_lowres-web.jpg&quot; alt=&quot;Ryder System, Inc. CEO John J. Diez&quot; /&gt;&lt;p style=&quot;font-size:85%;&quot;&gt;Ryder System, Inc. CEO John J. Diez&lt;/p&gt;&lt;/div&gt;&lt;table cellspacing=&quot;0&quot; class=&quot;bwtablemarginb bwblockalignl bwwidth100&quot;&gt;
&lt;tr&gt;
&lt;td class=&quot;bwwidth10&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;b&gt;Who: &lt;/b&gt;&lt;/td&gt;
&lt;td class=&quot;bwvertalignt bwpadl0 bwwidth90&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;p class=&quot;bwcellpmargin&quot;&gt;
Ryder System, Inc. CEO John Diez

&lt;/p&gt;

&lt;/td&gt;

&lt;/tr&gt;
&lt;tr&gt;
&lt;td class=&quot;bwwidth10&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;b&gt;What:&lt;/b&gt;&lt;/td&gt;
&lt;td class=&quot;bwvertalignt bwpadl0 bwwidth90&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;p class=&quot;bwcellpmargin&quot;&gt;
Wells Fargo 16th Industrials &amp;amp; Materials Conference

&lt;/p&gt;

&lt;/td&gt;

&lt;/tr&gt;
&lt;tr&gt;
&lt;td class=&quot;bwwidth10&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;b&gt;When:&lt;/b&gt; &lt;/td&gt;
&lt;td class=&quot;bwvertalignt bwpadl0 bwwidth90&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ryder+CEO+John+Diez+to+Address+Wells+Fargo+16th+Industrials+%26amp%3B+Materials+Conference/26595130.html</guid>
   <pubDate>Wed, 03 Jun 2026 06:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular </title>
   <link>http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</guid>
   <pubDate>Tue, 02 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.06353047</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20403755</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular </title>
   <link>http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</guid>
   <pubDate>Tue, 02 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.06353047</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20403755</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular </title>
   <link>http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</guid>
   <pubDate>Tue, 02 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.06353047</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20403755</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular </title>
   <link>http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</guid>
   <pubDate>Tue, 02 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.06353047</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20403755</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular </title>
   <link>http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</guid>
   <pubDate>Tue, 02 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.06353047</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20403755</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular </title>
   <link>http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</guid>
   <pubDate>Tue, 02 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.06353047</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20403755</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular </title>
   <link>http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</guid>
   <pubDate>Tue, 02 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.06353047</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20403755</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular </title>
   <link>http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</guid>
   <pubDate>Tue, 02 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.06353047</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20403755</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular </title>
   <link>http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</guid>
   <pubDate>Tue, 02 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.06353047</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20403755</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular </title>
   <link>http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html</guid>
   <pubDate>Tue, 02 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.06353047</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20403755</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Form  4          RYDER SYSTEM INC          For: May 29  Filed by: Fatovic Robert D</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RYDER+SYSTEM+INC++++++++++For%3A+May+29++Filed+by%3A+Fatovic+Robert+D/26584560.html</link>
   <description>si-local-file:///var/storage/secattach/20260601/26584560.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RYDER+SYSTEM+INC++++++++++For%3A+May+29++Filed+by%3A+Fatovic+Robert+D/26584560.html</guid>
   <pubDate>Mon, 01 Jun 2026 16:44:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Form  4          RYDER SYSTEM INC          For: May 29  Filed by: Fatovic Robert D</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RYDER+SYSTEM+INC++++++++++For%3A+May+29++Filed+by%3A+Fatovic+Robert+D/26584560.html</link>
   <description>si-local-file:///var/storage/secattach/20260601/26584560.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RYDER+SYSTEM+INC++++++++++For%3A+May+29++Filed+by%3A+Fatovic+Robert+D/26584560.html</guid>
   <pubDate>Mon, 01 Jun 2026 16:44:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Form  4          RYDER SYSTEM INC          For: May 27  Filed by: HODES SANFORD J.</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RYDER+SYSTEM+INC++++++++++For%3A+May+27++Filed+by%3A+HODES+SANFORD+J./26576639.html</link>
   <description>si-local-file:///var/storage/secattach/20260529/26576639.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RYDER+SYSTEM+INC++++++++++For%3A+May+27++Filed+by%3A+HODES+SANFORD+J./26576639.html</guid>
   <pubDate>Fri, 29 May 2026 17:22:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Form  4          RYDER SYSTEM INC          For: May 27  Filed by: HODES SANFORD J.</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RYDER+SYSTEM+INC++++++++++For%3A+May+27++Filed+by%3A+HODES+SANFORD+J./26576639.html</link>
   <description>si-local-file:///var/storage/secattach/20260529/26576639.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RYDER+SYSTEM+INC++++++++++For%3A+May+27++Filed+by%3A+HODES+SANFORD+J./26576639.html</guid>
   <pubDate>Fri, 29 May 2026 17:22:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Form  144        RYDER SYSTEM INC                       Filed by: Fatovic Robert D</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++144++++++++RYDER+SYSTEM+INC+++++++++++++++++++++++Filed+by%3A+Fatovic+Robert+D/26574875.html</link>
   <description>si-local-file:///var/storage/secattach/20260529/26574875.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++144++++++++RYDER+SYSTEM+INC+++++++++++++++++++++++Filed+by%3A+Fatovic+Robert+D/26574875.html</guid>
   <pubDate>Fri, 29 May 2026 16:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Form  144        RYDER SYSTEM INC                       Filed by: Fatovic Robert D</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++144++++++++RYDER+SYSTEM+INC+++++++++++++++++++++++Filed+by%3A+Fatovic+Robert+D/26574875.html</link>
   <description>si-local-file:///var/storage/secattach/20260529/26574875.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++144++++++++RYDER+SYSTEM+INC+++++++++++++++++++++++Filed+by%3A+Fatovic+Robert+D/26574875.html</guid>
   <pubDate>Fri, 29 May 2026 16:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Form  144        RYDER SYSTEM INC                       Filed by: HODES SANFORD J.</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++144++++++++RYDER+SYSTEM+INC+++++++++++++++++++++++Filed+by%3A+HODES+SANFORD+J./26565057.html</link>
   <description>si-local-file:///var/storage/secattach/20260528/26565057.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++144++++++++RYDER+SYSTEM+INC+++++++++++++++++++++++Filed+by%3A+HODES+SANFORD+J./26565057.html</guid>
   <pubDate>Thu, 28 May 2026 13:39:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
 </channel>
</rss>
